These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2276437)

  • 1. Regulation of epidermal growth factor receptor in breast cancer.
    Barker S; Panahy C; Puddefoot JR; Goode AW; Vinson GP
    Biochem Soc Trans; 1990 Aug; 18(4):562-4. PubMed ID: 2276437
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.
    Nicholson RI; Hutcheson IR; Harper ME; Knowlden JM; Barrow D; McClelland RA; Jones HE; Wakeling AE; Gee JM
    Endocr Relat Cancer; 2001 Sep; 8(3):175-82. PubMed ID: 11566608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptors in human breast cancer.
    Harris AL; Nicholson S
    Cancer Treat Res; 1988; 40():93-118. PubMed ID: 2908663
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7.
    Berthois Y; Dong XF; Martin PM
    Biochem Biophys Res Commun; 1989 Feb; 159(1):126-31. PubMed ID: 2784313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of estrogen receptor and epidermal growth factor receptor mRNAs by phorbol ester in MCF 7 breast cancer cells.
    Lee CS; Koga M; Sutherland RL
    Biochem Biophys Res Commun; 1989 Jul; 162(1):415-21. PubMed ID: 2751660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
    Nicholson RI; Hutcheson IR; Harper ME; Knowlden JM; Barrow D; McClelland RA; Jones HE; Wakeling AE; Gee JM
    Ann N Y Acad Sci; 2002 Jun; 963():104-15. PubMed ID: 12095935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of gene expression involved in the progression of human breast cancer to hormone independence.
    van Agthoven T; van Agthoven TL; Foekens JA; Dorssers LC
    Ann N Y Acad Sci; 1993 Jun; 684():250-2. PubMed ID: 7686358
    [No Abstract]   [Full Text] [Related]  

  • 8. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
    Boylan M; van den Berg HW; Lynch M
    Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells.
    Biswas DK; Cruz AP; Gansberger E; Pardee AB
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8542-7. PubMed ID: 10900013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
    J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity.
    Freiss G; Rochefort H; Vignon F
    Biochem Biophys Res Commun; 1990 Dec; 173(3):919-26. PubMed ID: 2268352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line.
    Long B; McKibben BM; Lynch M; van den Berg HW
    Br J Cancer; 1992 Jun; 65(6):865-9. PubMed ID: 1616857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling.
    Sirinian C; Papanastasiou AD; Schizas M; Spella M; Stathopoulos GT; Repanti M; Zarkadis IK; King TA; Kalofonos HP
    Oncogene; 2018 Sep; 37(37):5101-5114. PubMed ID: 29844572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells.
    Sehgal I; Bailey J; Hitzemann K; Pittelkow MR; Maihle NJ
    Mol Biol Cell; 1994 Mar; 5(3):339-47. PubMed ID: 8049525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer.
    Sainsbury JR; Malcolm AJ; Appleton DR; Farndon JR; Harris AL
    J Clin Pathol; 1985 Nov; 38(11):1225-8. PubMed ID: 2999195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor in breast cancer.
    Barker S; Vinson GP
    Int J Biochem; 1990; 22(9):939-45. PubMed ID: 2282963
    [No Abstract]   [Full Text] [Related]  

  • 17. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer.
    Sainsbury JR; Farndon JR; Sherbet GV; Harris AL
    Lancet; 1985 Feb; 1(8425):364-6. PubMed ID: 2857419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.
    Oh AS; Lorant LA; Holloway JN; Miller DL; Kern FG; El-Ashry D
    Mol Endocrinol; 2001 Aug; 15(8):1344-59. PubMed ID: 11463858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas.
    Cattoretti G; Andreola S; Clemente C; D'Amato L; Rilke F
    Br J Cancer; 1988 Apr; 57(4):353-7. PubMed ID: 3291921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.
    Wang L; Wang ZY
    Oncol Rep; 2010 Apr; 23(4):1109-17. PubMed ID: 20204298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.